European Archives - Page 967 of 1494 - European Medical Journal

EMJ 6.1 Feature Image

The Treatment Landscape of Atopic Dermatitis: Interviews with Three Consultant Dermatologists

Atopic dermatitis (AD), sometimes referred to as ‘atopic eczema’, is a common, chronic, pruritic, Type II inflammatory skin disease which is associated…

Is CD37-Targeted Therapy a Viable Alternative in the Treatment of Diffuse Large B-cell Lymphoma? Interviews with Two Key Opinion Leaders

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and the most frequent non-Hodgkin lymphoma (NHL) in adults, accounting for 30–40%…

Transient Cutaneous Alterations of the Newborn

At birth, the skin of the newborn suddenly comes into contact with the extrauterine world: a dry and aerobic environment.1 Newborn skin is 40–60%…

EMJ 6.1 Feature Image

Rare 2030 Final Policy Conference: Summary of the Recommendations of the Rare 2030 Foresight Study

IMPROVING the lives of people living with a rare disease in Europe has been an overarching aim of the Rare 2030 Foresight Study, a two-year study…

Performance of Different Criteria Sets for Inflammatory Back Pain in Radiographic

It is important to recognise inflammatory back pain (IBP) for early diagnosis of ankylosing spondylitis (AS). The aims of this study were to develop….

Can Blocking Nef Proteins Treat Immunodeficiency in HIV?

IMMUNODEFIENCY in patients with HIV may be counteracted by drugs that block protein kinases, according to a new study carried out by researchers at the…

Advanced CAR T-Cell Therapy for Multiple Myeloma

PROMISING results of a newly advanced chimeric antigen receptor (CAR) T-cell therapy showed that more than triple the period remission for multiple myeloma.

An Interview with Major (Retd) Sally Orange

Sally Orange, | Physiotherapist | Endurance Runner | Mental Health Champion

EMJ Podcast: Decisions, Development, and Devices

Dr. Brian Dunkin, Chief Medical Officer, Boston Scientific, explores the advancements in minimally invasive surgery, reflects on the growth of telemedicine, and considers the science behind recruitment and embedding culture within organisations.

Talking to José Maria Guido Avila

José Maria Guido Avila, Global Lead HCP Marketing, Sanofi, shares his thoughts on appropriate metrics measure the success of virtual events.